Introduction India’s regulatory landscape for biologic and biosimilar medicines continues to evolve. In response to scientific advances and accumulated regulatory experience, the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) have jointly released the Draft Guidelines on Similar Biologics – Regulatory Requirements for Marketing Authorization in India, 2025. These proposed guidelines […]